Lv2
110 积分 2023-10-16 加入
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)
15天前
已完结
The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy
15天前
已完结
Transarterial radioembolisation combined with targeted therapy and immune checkpoint inhibitors in advanced hepatocellular carcinoma with portal vein tumour thrombus: efficacy, safety, and dosimetric analysis
25天前
已完结
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma
2个月前
已完结
Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis
2个月前
已完结
Integrating Multiple Outcomes of First-Line Immunotherapy-Based Regimens for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials
3个月前
已完结
Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab
4个月前
已关闭
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
4个月前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
4个月前
已完结
Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
4个月前
已完结
皖公网安备34019202002308
